North Cumbria Integrated Care NHS Foundation Trust, Penrith CA11 8HX, UK.
South Tyneside and Sunderland NHS Foundation Trust, Sunderland SR4 7TP, UK.
Clin Neurol Neurosurg. 2024 Apr;239:108210. doi: 10.1016/j.clineuro.2024.108210. Epub 2024 Feb 27.
Assess the efficacy, and potential impact of patient positioning for 10 minutes immediately post-procedure, of greater occipital nerve (GON) block for treatment of migraine.
Prospective multicentre non-blinded randomised controlled trial, randomisation and treatment of 60 neurology clinic patients with poorly controlled migraine. Outcomes measured with Headache Impact Test-6 (HIT-6), modified MIgraine Disability Assessment Scale (M-MIDAS), and RELIEF scores.
Patient positioning did not lead to significant difference in RELIEF score (34% vs 11%, p-value 0.10, Chi-squared test) at day 90. When considered in a multiple regression analysis, the sitting position outperformed supine position significantly (p-value 0.04). However, no significant difference in HIT-6 score between the supine (n = 27) and sitting position groups (n = 33) was detected at baseline (p-value 0.76), day 30 (p-value 0.69) or day 90 (p-value 0.54, Mann-Whitney U-test). The HIT-6 score significantly improved post-GON block, from median 67 (baseline pre-GON) to 59 (day 30) and 62 (day 90) for the supine group and a score of 66, 61-62 for the sitting group (all p-value ≤ 0.001, intra-group comparison using Wilcoxon test); M-MIDAS achieved similar outcomes. Overall, a significant minimal clinically important improvement was obtained with GON block, and the GON injections were deemed very tolerable by patients (median score of 2 on 10 cm pain scale).
Regardless of patient positioning, GON block is an effective and near-painless procedure for migraine symptom control. Unlike earlier published observational study data, this trial concludes that a sitting patient position immediately post-GON is preferred.
评估在大枕神经(GON)阻滞治疗偏头痛后立即 10 分钟内患者体位对治疗效果的影响。
前瞻性多中心非盲随机对照试验,对 60 名神经科诊所中偏头痛控制不佳的患者进行随机分组和治疗。采用头痛影响测试-6 (HIT-6)、改良偏头痛残疾评估量表(M-MIDAS)和 RELIEF 评分来评估疗效。
在第 90 天,患者体位并未导致 RELIEF 评分(34%比 11%,p 值为 0.10,卡方检验)有显著差异。在多回归分析中,坐姿显著优于仰卧位(p 值为 0.04)。然而,在基线(p 值为 0.76)、第 30 天(p 值为 0.69)和第 90 天(p 值为 0.54,Mann-Whitney U 检验)时,仰卧位组(n = 27)和坐姿组(n = 33)之间 HIT-6 评分无显著差异。GON 阻滞后 HIT-6 评分显著改善,从基线时的 67 分(GON 阻滞前)降至 30 天时的 59 分和 90 天时的 62 分(仰卧位组,所有 p 值均≤0.001,Wilcoxon 检验组内比较),而坐姿组的评分则为 66 分、61-62 分(所有 p 值均≤0.001,Wilcoxon 检验组内比较);M-MIDAS 也取得了类似的结果。总体而言,GON 阻滞治疗偏头痛症状控制有明显的最小临床意义改善,并且患者认为 GON 注射非常耐受(疼痛评分 10cm 上的中位数评分为 2 分)。
无论患者体位如何,GON 阻滞都是一种有效且几乎无痛的偏头痛治疗方法。与早期发表的观察性研究数据不同,本试验得出的结论是,GON 阻滞后患者采取坐姿更优。